News

Glenmark Pharmaceuticals announced that the 48th Annual General Meeting(AGM) of the company will be held on 11 September 2026.

Net profit of Glenmark Pharmaceuticals rose 930.34% to Rs 482.92 crore in the quarter ended June 2026 as against Rs 46.87 crore during the previous quarter ended June 2025. Sales rose 28.52% to Rs 3931.73 crore in the quarter ended June 2026 as against Rs 3059.33 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales3931.733059.33 29 OPM %20.4718.98 - PBDT816.56548.73 49 PBT643.39418.81 54 NP482.9246.87 930 Powered by Capital Market - Live News

Glenmark Specialty S.A. (Glenmark) today announced that U.S. FDA has approved the expanded use of RYALTRIS� (olopatadine hydrochloride and mometasone furoate) Nasal Spray, 665 mcg/25 mcg per spray, for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years. With this approval, RYALTRIS� is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population.

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. Glenmark`s Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa�2 IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253]. According to IQVIA� sales data for the 12-month period ending May 2026, the Zyprexa� IntraMuscular Injection market achieved annual sales of approximately $25.4 million.